- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT05358379
A Study to Investigate THT140, in Subjects With Advanced Solid Tumors and Lymphoma
A Phase 1/2, Open-label, Multicenter Study to Investigate the Safety, Pharmacokinetics, and Efficacy of THT140, an Oral PLK1 Inhibitor, in Subjects With Advanced Solid Tumors and Lymphoma
This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of THT40 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma with a focus on tumors with ARID1A and similar mutations who have progressed despite having received standard therapy or for whom no standard therapy exists.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Phase 1 part of the study will consist of a dose-escalation and a dose-finding component. Phase 1 also includes expansion cohorts for subject with ARID1A and similar mutations.
Phase 2 will enroll subjects with locally advanced, recurrent, or metastatic, histologically confirmed advanced solid tumors or lymphoma, who have failed all standard therapies or for whom standard therapy does not exist, into 8 groups:
Group 1: Bladder cancer
Group 2: Breast cancer: Triple-negative breast cancer (TNBC)
Group 3: Lung cancer (non-small cell lung cancer [NSCLC] and small cell lung cancer [SCLC])
Group 4: Hepatocellular carcinoma (HCC) and biliary tract cancer (BTC)
Group 5: Metastatic colorectal cancer (mCRC) including KRAS-mutated mCRC
Group 6: B-cell lymphoma including diffuse large B-cell lymphoma (DLBCL)
Group 7: T-cell lymphoma (cutaneous T-cell lymphoma [CTCL] and peripheral T-cell lymphoma [PTCL])
Group 8: Basket cohort: tumor types that are suspected to have a related mechanism of action but are not included in previous groups including, esophageal, prostate, ovarian and pancreatic cancers
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
- Fase 1
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Mark H Kirschbaum, MD
- Número de teléfono: 626-316-3394
- Correo electrónico: mark.kirschbaum@tethrabio.com
Copia de seguridad de contactos de estudio
- Nombre: Jason Summa
- Correo electrónico: jason.summa@tethrabio.com
Ubicaciones de estudio
-
-
-
Seoul, Corea del Sur
- Aún no reclutando
- Seoul National University Hospital
-
Contacto:
- Do-Youn Oh, Prof. MD
- Número de teléfono: +82-2-2072-0701
- Correo electrónico: ohdoyoun@snu.ac.kr
-
-
-
-
-
Barcelona, España
- Aún no reclutando
- Hospital Universitario Vall d'Hebron
-
Contacto:
- Maria Vieito, MD
- Correo electrónico: Mvieito@vhio.net
-
-
-
-
New York
-
New York, New York, Estados Unidos, 10065
- Reclutamiento
- Memorial Sloan Kettering Cancer Center (MSKCC)
-
Contacto:
- Horwitz Steven, MD
- Número de teléfono: +1 646-608-2680
- Correo electrónico: Horwitzs@mskcc.org
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- MD Anderson Cancer Center
-
Contacto:
- Rabia Khan
- Número de teléfono: +1 713-563-4667
- Correo electrónico: RKhan@mdanderson.org
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Reclutamiento
- Fred Hutchinson Cancer Center/ University of Washington
-
Contacto:
- Gentry GT King, MD
- Correo electrónico: gking@fredhutch.org
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
Males or females aged ≥ 18 years.
-
Subjects with histological- or cytological-confirmed, advanced cancer who have progressed on (or not been able to tolerate) standard therapy or for whom no standard anticancer therapy exists
- For Phase 1, all tumor types may be enrolled
- For Phase 2, subjects will be enrolled as per the study design section above
-
ECOG performance status of 0-2.
-
Subjects who relapsed post-autologous or post-allogeneic transplant are eligible. Post-transplant subjects must be without active fungal disease or significant acute graft-versus-host disease
-
Women of childbearing potential (WOCBP) must have a negative pregnancy test (urine or serum) within 7 days prior to starting the study drug. Both males and females must agree to use effective birth control during the study (prior to the first dose and for 6 months after the last dose) if conception is possible during this interval.
-
Subjects must be able to swallow and retain orally administered medication and not have any clinically significant GI abnormalities that may alter the absorption, such as malabsorption syndrome or major resection of the stomach or bowels.
-
Able to agree to and sign the informed consent and to comply with the protocol.
Exclusion Criteria:
-
Subjects with a history of brain metastases or who have signs/symptoms attributable to brain metastases and have not been assessed with radiologic imaging to rule out the presence of brain metastases. Subjects with treated brain metastases that are asymptomatic and have been clinically stable for at least 4 weeks will be eligible.
-
Subjects who have not received vaccines for severe acute respiratory syndrome-corona virus-2 (SARS-COV-2) and have suspected signs and symptoms of the novel coronavirus infection (COVID-19) or have confirmed COVID-19.
-
Subjects with a history of another primary malignancy, other than:
- In situ carcinomas, e.g., breast, cervix, and prostate
- Locally excised nonmelanoma skin cancer
- No evidence of disease from another primary cancer for 2 or more years and has not taken any anti-cancer treatment in 2 years.
-
Any other clinically significant acute or chronic medical or psychiatric condition or any laboratory abnormality that may increase the risk associated with study drug administration or may interfere with the interpretation of study results.
-
Diseases that significantly affect GI absorption of THT140.
-
Subjects who have impaired cardiac function or clinically significant cardiac disease.
-
Presence of active chronic inflammatory bowel disease (ulcerative colitis, Crohn's disease) or GI perforation within 6 months of enrollment
-
Presence of an active infection requiring intravenous antibiotics
-
Presence of known history of human immunodeficiency virus-1/2 with uncontrolled viral load and on medications that may interfere with metabolism
-
Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV).
-
Chemotherapy, biologic therapy, targeted therapy, immunotherapy, extended-field radiotherapy, or investigational agents within 5 half-lives or 3 weeks (whichever is shorter) prior to administration of first dose of study drug on Day 1 or have not recovered from the side effects of such therapy.
-
Major surgery/surgical therapy for any cause within 4 weeks of the first dose
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación Secuencial
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Phase 1 Dose Escalation
Phase 1 = THT140 administered orally in escalating doses starting at 5mg QD M-F week 1 to 3 for 3 weeks of a 4 week cycle. Subsequent cohorts will escalate in dose and schedule until optimized phase 2 dose and schedule is achieved. |
THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
Otros nombres:
|
|
Experimental: Phase 2
Phase 2 = Recommended THT140 phase 2 dose and schedule administered orally in 28-day cycles. |
THT140 is a highly selective, orally- and intravenously- available, ATP-competitive inhibitor of PLK1.
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Maximum tolerated dose
Periodo de tiempo: 6 months
|
The incidence rate of dose-limiting toxicities (first cycle only) at each dose level |
6 months
|
|
Overall Response Rate (ORR)
Periodo de tiempo: 18 months
|
Assessment of response criteria according to RESIST, Lugano or mSWAT. |
18 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Adverse events
Periodo de tiempo: 24 months
|
Type, frequency, and severity of adverse drug reactions |
24 months
|
|
AUC
Periodo de tiempo: 6 months
|
THT140 plasma concentrations |
6 months
|
|
Cmax
Periodo de tiempo: 6 months
|
THT140 plasma concentrations |
6 months
|
|
Tmax
Periodo de tiempo: 6 months
|
THT140 plasma concentrations |
6 months
|
|
T1/2
Periodo de tiempo: 6 months
|
THT140 plasma concentrations |
6 months
|
|
Disease Control Rate
Periodo de tiempo: 24 months
|
To evaluate the disease control rate (DCR) in subjects receiving THT140. |
24 months
|
|
Duration of Response
Periodo de tiempo: 24 months
|
To evaluate the duration of response (DOR) in subjects receiving THT140. |
24 months
|
|
Progression-free Survival
Periodo de tiempo: 24 months
|
To evaluate progression-free survival (PFS) in subjects receiving THT140. |
24 months
|
|
Overall Survival
Periodo de tiempo: 24 months
|
To evaluate overall survival (OS) in subjects receiving THT140. |
24 months
|
Otras medidas de resultado
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Pharmacodynamics
Periodo de tiempo: 6 months
|
Pharmacodynamic response to THT140 will be assessed by mRNA sequencing of blood samples to determine differential expression of PLK1 target genes (including MYC, PLK1, CDKN1A) relative to baseline. |
6 months
|
|
Pharmacogenomics
Periodo de tiempo: 24 months
|
Genomic alterations will be assessed by next generation sequencing (NGS) at baseline and various time points during treatment with THT140 in order to investigate the relationship between genetic alterations in THT140 related pathways and response to THT140. Parameters of genetic variations (DNA mutations) and copy number variations using plasma cell-free DNA derived from peripheral blood will be assessed. |
24 months
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- THT140-101
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .